44 results about "Heart dysfunction" patented technology

Systems and methods are provided for monitoring and processing physiological signals (e.g., electrocardiogram signals) to detect and predict for possible dysfunction of an anatomical feature (e.g., cardiac dysfunction) or otherwise predict a likelihood of future cardiac dysfunction of the individual. For example, a system comprises a plurality of sensors, a physiological signal processing system, and a feature analysis system. The sensors are configured to monitor physiological signals from an individual that has undergone a medical procedure on an anatomical feature. The physiological signal processing system is configured to analyze the physiological signals and extract features from the physiological signals which are indicative of a function of the anatomical feature. The feature analysis system is configured to analyze the extracted features and predict a risk of the individual developing a post-procedural dysfunction of the anatomical feature as a result of the medical procedure on the anatomical feature.

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.

The invention discloses application of ADAMTS4 as a biomarker of sepsis with cardiac dysfunction, AUCROC is equal to 0.930, 95% CI is 0.859-1.000 in diagnosis of sepsis with cardiac dysfunction as the biomarker, accuracy is high, and a new detection means and scheme are provided for diagnosis and prediction of sepsis with cardiac dysfunction.

The application discloses a medicine for warming yang, promoting water excretion and detoxification, and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The medicine for warming yang, promoting water excretion and detoxification provided by the application takes prepared aconite, dried ginger and fried licorice as monarch drugs to stimulate the vital energy of the whole body and supplement yang qi of the heart, spleen and kidney; takes rhubarb and soapberry thorn as minister drugs to clear heat, detoxify and dredge the triple energizer; takes cassia twig and poria as auxiliary drugs to warm yang, promote the circulation of qi, reduce edema and promote water excretion; and takes taizishen as a minister drug to supplement qi, remove dampness and regulate qi movement. The whole prescription can supplement deficiency and eliminate excess, and has the functions of warming yang, detoxification and water excretion. The medicine can treat the root "deficiency of yang qi and invasion of pathogenic factors" of sepsis heart dysfunction, achieve the effect of treating the root and branch at the same time, reduce the inflammation level, cTnT and BNP level of a patient, and achieve the treatment of sepsis heart dysfunction.

Methods of improving a heart function in a heart of a subject having heart dysfunction are described. An exemplary embodiment includes accessing a pericardial cavity of the heart and advancing a cutting device within the pericardial cavity to a first incision point. At least a parietal layer of a pericardium of the heart is then pierced. A cutting device is placed against the parietal layer and retracted along a selected cut path so as to create a first incision having a selected length in at least the parietal layer to reduce pressure exerted on the heart by the pericardium. The above operations are repeated to create one or more additional incisions along respective additional cut paths.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

This invention discloses the application of GW3965 in the preparation of drugs that alleviate cardiac damage caused by doxorubicin. Experiments have demonstrated that GW3965 can, while inhibiting tumor growth, alleviate cardiac dysfunction related to doxorubicin cardiotoxicity, reduce doxorubicin-induced cardiac fibrosis, and inhibit doxorubicin-induced cardiomyocyte atrophy and apoptosis. This suggests that GW3965 can alleviate cardiac damage caused by doxorubicin, increase the safety of doxorubicin chemotherapy, and has promising clinical application prospects.

The application discloses a kind of drug for treating heart toxicity caused by VEGFR inhibitor with CXCL12 gene or protein as target point, belongs to medical technology field.The drug reverses heart toxicity caused by VEGFR inhibitor by down-regulating the expression of CXCL12 gene or the accumulation of CXCL12 protein in heart.Specifically, the application provides shRNA, neutralizing antibody or small molecule drug targeting CXCL12 as drug for reversing heart toxicity caused by VEGFR inhibitor.The application provides new intervention target and effective strategy for intervention of heart dysfunction caused by VEGFR inhibitor such as lefratinib, and provides feasible medication scheme for clinic.

The present invention provides recombinant adeno-associated viral vectors which are enriched in the heart but have reduced enrichment in other organs, particularly the liver and CNS cells, for use in the treatment of acquired and genetic left and right heart diseases as well as other diseases associated directly or indirectly with cardiac dysfunction.

The present disclosure provides a system for screening therapeutic cardiac compounds in cells, tissues and organoids of patients with diseases such as neurological diseases or conditions with serious cardiac complications. The system comprises: a medical device apparatus suitable for single-layer screening of cardiac active compounds, which comprises a human ventricular cardiac anisotropic sheet (hvCAS) and a human ventricular cardiac tissue strip (hvCTS); a two-layer system further comprising a human ventricular cardiac organoid chamber (hvCOC); or a three-layer system further comprising a medical device with multiple organoids, which include the same or different types of tissues or organoids (e.g., heart, liver, pancreas, kidney). Another aspect of the present disclosure is a method suitable for use with the system, which comprises screening for compounds that have cardiac effects on cells, tissues or organoids of patients with non-cardiac diseases such as neurological diseases that exhibit cardiac effects. The method can also be used to evaluate the toxicity of compounds to various cells, tissues or organoids of such patients.

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt and / or solvate thereof for use in the prevention and / or treatment of heart failure, cardiomyopathy, myocardial infarction-induced cardiac dysfunction and / or for improving cardiac function in a subject in need thereof.

The invention discloses a ballistocardiogram-based abnormal cardiac function detection system and method and a medium, and relates to the field of abnormal cardiac function detection, and the system comprises a ballistocardiogram sensor which is used for collecting a ballistocardiogram signal of a person to be detected; the signal preprocessing module is used for preprocessing the heart impact signal; the feature extraction module is used for performing feature extraction on the preprocessed heart impact signal; and the heart function abnormality detection module is used for inputting the heart impact characteristics into the trained heart function abnormality detection model to obtain the risk of the cardiovascular adverse reaction event so as to remind the to-be-detected person to go to a hospital for heart function examination when the risk is relatively high. The ballistocardiogram sensor is used for collecting the ballistocardiogram signals of the person to be detected, the heart function abnormity detection module is used for analyzing the characteristics of the ballistocardiogram signals, the risk of cardiovascular adverse reaction events is obtained, and the detection convenience is improved under the condition that the detection accuracy is guaranteed.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

The invention discloses an application of an MODICA gene and / or an MODICA protein in preparation of a medicine for improving cardiac dysfunction. The invention provides a new target for treating cardiac dysfunction, overexpression of the MODICA can significantly relieve myocardial injury, inhibit fibrosis of cardiac tissues and reduce myocardial cell apoptosis, has great significance in clinical treatment of cardiac dysfunction related diseases and prevention of cardiovascular events caused by anti-tumor treatment, and has a wide application prospect. And a new technical choice is provided.

The invention discloses application of cornua cervi pantotrichum tissue-derived exosome-like nanoparticles in preparation of a medicine for preventing and treating senile cardiovascular diseases. A sterile, stable and high-purity cornua cervi pantotrichum tissue exosome is obtained by adopting an enzyme digestion-differential centrifugation-ultra-high-speed centrifugation combined method, the physiological efficacy of the cornua cervi pantotrichum tissue exosome in heart protection is studied, and it is found that the cornua cervi pantotrichum tissue exosome can significantly improve cardiac dysfunction of acute aging mice induced by D-galactose (D-Gal). The cardiac ejection function, the cardiac fibrosis and the inflammation invasion level are remarkably improved. The compound has treatment potential in preparation of medicines for preventing heart protection and treating heart diseases, and provides a new strategy and a treatment method for treating cardiovascular diseases of old people.

A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SEQ ID NO: 1), a truncated Lipocalin 10 (Lcn10) protein having the amino acid sequence SEQ ID NO: 2, Lcn 10-expressing vectors for full length / truncated Lcn10, or combinations thereof to the subject, The method is also useful for reducing the risk of a heart attack-induced cardiac dysfunction, atherosclerosis, inflammatory bowel disease or diabetes-induced cardiomyopathy.

(0199] Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of cancer therapy-related cardiac dysfunction (CTRCD). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for CTRCD, based on the identification of a CD36 mutation in a sample from the subject.

The invention discloses a novel application of acid-producing bacteroides, and particularly relates to an application of the acid-producing bacteroides as an active ingredient in preparation of a medicine for preventing and treating diabetic cardiomyopathy. It is found for the first time that acid-producing bacteroides treatment can effectively prevent and treat diabetic cardiomyopathy induced by type 1 diabetes mellitus, including improvement of cardiac dysfunction, fibrosis and intestinal barrier injury of diabetic cardiomyopathy, specifically, acid-producing bacteroides can relieve expansion of heart and ventricles, ejection fraction and fibrosis collagen deposition of cardiac blood vessels, and can effectively prevent and treat diabetic cardiomyopathy induced by type 1 diabetes mellitus and prevent and treat diabetic cardiomyopathy induced by type 1 diabetes mellitus. Meanwhile, normal arrangement of myocardial structures can be recovered, and inflammatory cell infiltration is relieved. In addition, the research finds that the acid-producing bacteroides improves mRNA expression of intestinal tight junction protein caused by the diabetic cardiomyopathy, improves the intestinal barrier function, inhibits expression of inflammatory factors and remarkably enhances the intestinal barrier function, and a new scheme is provided for prevention and treatment of the diabetic cardiomyopathy.

A method of determining a likelihood of developing cancer therapy-related cardiac dysfunction (CTRCD) in a subject receiving an anthracycline and / or HER2 targeted therapy cancer treatment. Also disclosed herein is a method for treating a subject who is identified as being at risk of developing CTRCD. This disclosure also relates to a method of identifying if a subject with cancer to be treated with or an anthracycline and / or a HER2 targeted therapy treatment is likely to benefit from a cardioprotective treatment. Further disclosed is a panel or kit, the panel or kit comprising a plurality of detection agents specific for each of a set of biomarkers in a sample obtained from a subject with cancer, optionally selected from: angiopoietin-2 (ANGPT2), Endoglin (ENG), E-selectin, endothelin-1 (ET-1), myeloperoxidase (MPO), Interferon gamma-induced protein-10 (IP-10) and Interferon-α, and optionally a solid support.

The invention relates to an application of an Adtrp virus in preparation of a medicine for treating heart failure. The invention discloses a gene therapy method for treating heart failure based on a myoAAV1A-Adtrp virus vector. According to the present invention, the deficiency of the whole genome Adtrp causes the heart dysfunction and the heart failure, the deficiency of the Adtrp further aggravates the heart dysfunction and the heart failure, the results show that the deficiency of the Adtrp causes the heart failure, the myoAAV1A-Adtrp gene therapy can effectively block the heart failure development Lepr, Apob and Col7a1 of the heart failure CAD and TAC model, the expression levels of the adhesion molecules Icam-1, Vcam-1, E-selectin, P-selectin and p65 are changed, and the MyoAAV1A-Adtrp gene therapy can reverse the effect; adtrp plays an important role in the pathogenesis of heart failure, and the MyoAAV1A-Adtrp gene is used for treating the heart failure, so that the heart dysfunction and the heart failure of CAD and TAC models can be obviously relieved.

The present invention discloses an application of TREM2hi macrophages in preparation of drugs for treating cardiac dysfunction, and belongs to the technical field of medicine. The present invention discloses for the first time that there is a kind of macrophage subsets for high expression of a triggering receptor expressed on myeloid cells-2 in cardiac derived macrophages, which has a strong function of recognizing and reducing mitochondrial damage and plays an important role in maintaining a cardiac metabolic balance. Therefore, the TREM2hi macrophages have important application value in treatment of the cardiac dysfunction.

Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and / or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.

Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

The application discloses an early evaluation system for diastolic heart dysfunction, and relates to the technical field of medical treatment. IVR and SR E ; a storage module is used for storing the normal reference ranges of SR IVR and SR E of healthy people in different age groups; an evaluation output module is used for comparing the SR IVR and SRE of the examinee with the normal reference ranges in the storage module, and outputting the early evaluation result of the diastolic heart dysfunction; the secondary screening is conducted on the hypertensive patients who cannot be diagnosed as having the diastolic heart dysfunction through the conventional ultrasound, so that the basis for early intervention is provided, and the incidence of the diastolic heart failure can be reduced.

A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.

The application belongs to the technical field of biological medicine, and specifically discloses a new use of Areg. The application discloses the following: a preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating myocardial infarction; the preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating heart dysfunction; a preparation for inhibiting expression of Areg is used for preparing a biological model of myocardial infarction or a biological model of adverse ventricular remodeling; a preparation for detecting expression level of Areg is used for preparing a product for screening (diagnosing) myocardial infarction. It is found that expression of Areg protein is increased after myocardial infarction of a mouse, and it is found that knocking out Areg can aggravate adverse ventricular remodeling after myocardial infarction of a mouse. It is verified that by increasing expression level of Areg protein, autophagosome formation is inhibited, myocardial cell apoptosis is reduced, loss of functional myocardial cells is reduced, thereby ventricular remodeling is improved, and heart function is protected.

The invention provides preparation of a phellinus igniarius extract and application of the phellinus igniarius extract in a product for improving and / or treating myocardial infarction, and belongs to the technical field of medicines. The invention provides an application of a phellinus igniarius extract in preparation of a product for improving and / or treating myocardial infarction. The product comprises any one or more than two of medicine, health food and functional food. In the invention, the phellinus igniarius extract can obviously reduce myocardial infarction area, improve cardiac dysfunction, improve myocardial hypertrophy symptom, reduce myocardial cell apoptosis, inhibit inflammatory response, inhibit myocardial cell fibrosis and improve oxidative stress level, so that the effect of efficiently improving and / or treating acute myocardial infarction is achieved; the death rate of acute myocardial infarction is reduced. The result of the embodiment shows that the phellinus igniarius alcohol extract and the phellinus igniarius extract can achieve a better effect in improving and / or treating acute myocardial infarction.

A medical device (500) is described and disclosed that includes an incision assembly coupled to the distal end of a catheter (129) and an introducer coupled to and projecting from the incision assembly. Also described and disclosed is a method for improving cardiac function in a subject having cardiac dysfunction, the method including forming at least one incision length through the pericardium and reducing the pressure exerted by the pericardium on the heart.